Swedish Orphan Biovitrum AB (SWTUY.PK) announced earnings for its first quarter that increased from last year
The company's earnings came in at SEK875 million, or SEK2.52 per share. This compares with SEK800 million, or SEK2.33 per share, last year.
Excluding items, Swedish Orphan Biovitrum AB reported adjusted earnings of SEK944 million or SEK2.72 per share for the period.
The company's revenue for the period rose 3.3% to SEK6.465 billion from SEK6.256 billion last year.
Swedish Orphan Biovitrum AB earnings at a glance (GAAP) :
-Earnings: SEK875 Mln. vs. SEK800 Mln. last year.-EPS: SEK2.52 vs. SEK2.33 last year.-Revenue: SEK6.465 Bln vs. SEK6.256 Bln last year.
Commenting on the first-quarter results, Guido Oelkers, CEO of Swedish Orphan Biovitrum, said: "We continued our solid growth trajectory in the first quarter, with 3 percent growth at CER in the overall portfolio. The portfolio grew 23 percent at CER, excluding the RSV seasonal products and discontinued ReFacto manufacturing revenue in Q1 2024."
Looking ahead, for the full year, the company has reaffirmed its guidance. Swedish Orphan Biovitrum still expects its revenue to grow by a high single-digit percentage at CER. The company also anticipates its annual adjusted EBITA margin to be in the mid-30s percentage of revenue.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.